Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients
Status:
Completed
Trial end date:
2018-12-27
Target enrollment:
Participant gender:
Summary
With the availability of well-studied once-daily formulations of tacrolimus, the ability to
achieve a true once-daily immunosuppressant regimen along with everolimus and steroids may
finally be achievable and have the potential to optimize immunosuppression safety and
efficacy in kidney transplantation.